Cardlytics’ (CDLX) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Cardlytics (NASDAQ:CDLX) in a research note published on Thursday morning,Benzinga reports.

A number of other equities analysts have also recently issued reports on CDLX. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Evercore ISI initiated coverage on Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Bank of America lowered shares of Cardlytics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $4.00 to $3.50 in a report on Thursday, August 15th. Northland Securities cut shares of Cardlytics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. Finally, Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.92.

Cardlytics Stock Up 7.4 %

Shares of CDLX stock opened at $4.37 on Thursday. Cardlytics has a 1 year low of $2.89 and a 1 year high of $20.52. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.77 and a current ratio of 1.77. The business’s fifty day moving average is $3.69 and its 200-day moving average is $6.66. The stock has a market cap of $222.09 million, a PE ratio of -0.72 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 93.64%. Cardlytics’s revenue was down 15.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.26) EPS. Equities analysts expect that Cardlytics will post -1.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at approximately $687,298.15. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott A. Hill acquired 40,000 shares of the company’s stock in a transaction on Monday, August 12th. The stock was acquired at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $143,200. The disclosure for this purchase can be found here. Insiders sold a total of 43,573 shares of company stock valued at $151,612 in the last quarter. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Cardlytics

A number of institutional investors have recently bought and sold shares of CDLX. GSA Capital Partners LLP raised its stake in Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after acquiring an additional 354,474 shares in the last quarter. Renaissance Technologies LLC increased its position in Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares in the last quarter. Kent Lake Capital LLC bought a new position in Cardlytics in the 1st quarter valued at approximately $3,622,000. Perbak Capital Partners LLP acquired a new stake in Cardlytics in the first quarter valued at approximately $2,348,000. Finally, Blackstone Inc. bought a new stake in shares of Cardlytics during the first quarter worth $2,029,000. Institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.